Document:

EX-10.1

 Exhibit 10.1 

PATENT OPTION AGREEMENT 

Duke University File(s) #4719, 5000, 5191, 5204, 6381, 6382, 6478, 

6479, 6480, 6622, 6623, 6624, 6625 and 7094 

This Patent Option Agreement (“Agreement”) is entered into on June 9, 2020 (“EFFECTIVE DATE”), between Duke
University, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”) having the address in Article 8 below and Cryo-Cell International, Inc. (“COMPANY”), a corporation incorporated in
the state of Delaware, located at 700 Brooker Creek Blvd, Suite 1800, Oldsmar, Florida 34677. 
 DUKE desires to grant COMPANY the right to
license DUKE’s patent rights, regulatory data, and proprietary processes related to cord blood, cord tissue and DUOC-01 on substantially the terms set forth in this Agreement and the SUMMARY TERM SHEET
attached hereto at Attachment A, and COMPANY desires a period of time in which to enter into such license (the “License Agreement”). DUKE and COMPANY therefore agree as follows: 

ARTICLE 1 - DEFINITIONS 
 The following
definitions apply to this Agreement: 
 1.1 “EXCLUDED FIELDS OF USE” means autologous specific therapeutics for autism, cerebral palsy and stroke.

 1.2 “EXCLUDED TERRITORY” means Japan, South Korea, and Taiwan. 

1.3 “FIELD OF USE” means the treatment, prevention, cure, reduction, mitigation or other management of any and all diseases and conditions in humans.

 1.4 “LICENSED PRODUCT(S)” means any product sold by LICENSEE or SUBLICENSEE that: (a) but for the license under the License Agreement
comprises an infringement of (including contributory or inducement), or is covered by, a VALID CLAIM contained in the PATENT RIGHTS in the country in which any such product or product part is made, used, imported, offered for SALE or sold; or
(b) is manufactured or is required to be administered to a patient in the process of conducting a LICENSED PROCESS or is required to be employed to practice a LICENSED PROCESS; or (c) uses any of the REGULATORY DATA or TECHNICAL
INFORMATION. For clarity, any product lawfully sold by a third party without license or authorization from LICENSEE or a SUBLICENSEE shall not be a LICENSED PRODUCT. 

1.5 “LICENSED PROCESS(ES)” means any process or method or service employed by LICENSEE or SUBLICENSEE that: (a) but for the license under the
License Agreement comprises an infringement of (including contributory or inducement), or is covered by a VALID CLAIM contained in the PATENT RIGHTS in the country in which such process or method or service is performed; or (b) employs a
LICENSED PRODUCT; or (c) uses any of the REGULATORY DATA or TECHNICAL INFORMATION . 

  
 1 

 1.6 “LICENSED RIGHTS” means individually and collectively, REGULATORY DATA, TECHNICAL INFORMATION,
and PATENT RIGHTS. 
 1.7 “PATENT RIGHTS” means DUKE’s legal rights under the patent laws of the United States or relevant foreign countries
for all of the following: 
 (a) the following United States and foreign patents and/or patent applications, and divisionals, continuations
(including continuations-in-part only to the extent such continuations-in-part are
entitled to claim priority to such patents or patent applications), and foreign counterparts of the same: 
 Patent Rights Group (A) 

 

	 	•	 	 METHODS OF TREATING BRAIN INJURY USING CORD BLOOD OR A COMPONENT THEREOF, US Application 16/477,110 (4719)

  

	 	•	 	 COMPOSITIONS AND METHODS OF THE TREATMENT OF DEMYLINATING CONDITIONS, US Application 16/477,167, EP 18738872.3
(5000/5191) 

  

	 	•	 	 METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS, PCT/US2018/022174, US Application 16/493,754 (5204)

 Patent Rights Group (B) 
  

	 	•	 	 METHODS OF TREATING CEREBRAL PALSY USING HIGH DOSE ALLOGENEIC UMBILICAL CORD BLOOD, US Application 16/510,387
(6479) 

  

	 	•	 	 METHODS OF TREATING CEREBRAL PALSY AND HYPOXIC-ISCHEMIC ENCEPHALOPATHY USING HUMAN UMBILICAL CORD TISSUE-DERIVED
MESENCHYMAL STROMAL CELLS, PCT/US2019/025796 (6381) 

  

	 	•	 	 METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL
STROMAL CELLS, PCT/US2019/025716 (6382) 

  

	 	•	 	 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINATING CONDITIONS US Application 16/510,395

  

	 	•	 	 COMPOSITIONS COMPRISING MESESCHYMAL STROMAL CELLS FOR THE TREATMENT OF VIRAL INFECTIONS US application 63/017,290

 (b) United States and foreign patents issued from the applications listed in subsection 1.8(a) above, including any reissued or
reexamined patents based upon the same and all extensions, renewals, restorations and supplementary protection or any equivalent thereof. 
 1.8
“PRINCIPAL INVESTIGATOR” means Dr. Joanne Kurtzberg. 
 1.9 “REGULATORY DATA” means the underlying data, including any
correspondence, records, filings and other documentation with any regulatory authority with respect to any LICENSED PROCESS,, to the extent owned by and/or (if any) licensed (with the right to license COMPANY) to DUKE under United States and
international law, in any protocols, Standard Operating Procedures, and case report forms collected or created in connection with DUKE’s 

  
 2 

 pre-clinical studies, regulatory submissions, and clinical trials
(specifically IND numbers 14360, 16615, 15949, 17313, 17921, 16274, and 14753) and further includes any additional relevant TECHNICAL INFORMATION related to studies with Protocol Numbers 00017801, 00065043, 00052449, 00070514, 00079241, 00059284,
00077580, 00000412, and 00066647 including related reports, manuscripts and correspondence and other records of regulatory interactions communicated by DUKE to LICENSEE under the License Agreement and at DUKE’s sole discretion, with initial
reference in DUKE Office of Licensing and Ventures File Nos: 6480, 6622, 6623, 6624, and 6625. REGULATORY DATA and TECHNICAL INFORMATION shall not include the private medical records of individuals, and shall not include any data or information that
allows such individuals to be directly identified. 
 1.10 “TECHNICAL INFORMATION” means any non-patented
scientific, technical, regulatory and other information to the extent owned by and/or (if any) licensed (with the right to license to COMPANY) to DUKE and necessary or used by the PRINCIPAL INVESTIGATOR for the conduct of any process covered by the
PATENT RIGHTS. TECHNICAL INFORMATION does not include information in the public domain, as LICENSEE can show by documentary evidence. 
 1.11 “VALID
CLAIM” means: (a) a claim in an issued patent within the PATENT RIGHTS which has not (i) expired, (ii) been finally adjudicated or admitted by DUKE as invalid or unenforceable, or (iii) been abandoned, or (b) a claim in a
pending application within the PATENT RIGHTS which is still under prosecution; provided that if a claim of a pending patent application has not issued as a claim of an issued patent within seven (7) years after the filing date from which such
claim takes priority, such claim shall not be a VALID CLAIM for purposes of this Agreement from the seven (7) year anniversary date of such priority date until such time as such claim does issue (at which point such claim shall be a VALID CLAIM
for purposes of this Agreement). It is understood and agreed that a claim in a pending application that is subject to a restriction requirement during prosecution and is not yet being prosecuted as part of a divisional patent application will still
be considered a VALID CLAIM until it is finally rejected or abandoned and subject to the prior sentence. 
 ARTICLE 2 - EVALUATION

 2.1 During the OPTION PERIOD, COMPANY shall use commercially reasonable efforts to evaluate the market potential for LICENSED PRODUCTS and LICENSED
PROCESSES in the FIELD OF USE. 
 ARTICLE 3 - PATENT PROSECUTION AND MAINTENANCE 

3.1 DUKE shall control all aspects of filing, prosecuting, and maintaining all of the patents and patent applications included within the PATENT RIGHTS.
COMPANY shall fully cooperate in such activities. The parties shall negotiate in good faith the foreign countries in which to pursue patent protection. COMPANY shall not have any rights under this Agreement in countries with respect to which COMPANY
does not agree to reimburse DUKE’s documented, out-of-pocket patent expenses with respect to the prosecution and maintenance of the PATENT RIGHTS. 

  
 3 

 3.2 DUKE shall notify COMPANY of any significant information (including proposed responses or filings)
received by DUKE relating to the filing, prosecution and maintenance of the patents and patent applications included within the PATENT RIGHTS, and shall make reasonable efforts to allow COMPANY to review, comment, and advise upon such information.
COMPANY agrees to hold such information, including such information received before the EFFECTIVE DATE, confidential and to use the information provided by DUKE only for the purpose of advancing PATENT RIGHTS and shall return all such information to
DUKE if the parties do not enter into the License Agreement hereunder. With written permission from DUKE (not to be unreasonably withheld), COMPANY may share such information with third parties who are obligated as to confidentiality and use to the
same extent as COMPANY. 
 ARTICLE 4 - OPTION 

DUKE grants COMPANY an exclusive option to obtain: 

(a) an exclusive worldwide license under Patent Rights B to make, have made, use, import, offer for sale, sell and otherwise commercially
exploit LICENSED PRODUCTS and to practice LICENSED PROCESSES, and the exclusive right to use REGULATORY DATA and TECHNICAL INFORMATION in connection with such licensed patent rights, in the FIELD OF USE and TERRITORY; and 

(b) an exclusive license under Patent Rights A to make, have made, use, import, offer for sale, sell and otherwise commercially exploit
LICENSED PRODUCTS and to practice LICENSED PROCESSES, and the exclusive right to use REGULATORY DATA and TECHNICAL INFORMATION in connection with such licensed patent rights, in the FIELD OF USE and TERRITORY except for the EXCLUDED FIELDS OF USE in
the EXCLUDED TERRITORY. For clarity, COMPANY shall have no LICENSED RIGHTS under Patent Rights A for the EXCLUDED FIELDS OF USE in the EXCLUDED TERRITORY; and 

(c) in each case above with the right to sublicense; and 

(d) subject to DUKE’s reserved rights to practice the LICENSED RIGHTS for all research, public service, internal (including clinical)
and/or educational purposes; provided that PRINCIPLE INVESTIGATOR shall keep COMPANY reasonably informed with respect to any such practice and the results thereof and the COMPANY agrees to such activities, not to be unreasonably withheld. 

The following terms shall apply to the option: 
 4.1 OPTION
FEE. As consideration for the option granted herein, COMPANY shall pay DUKE a non-refundable, option fee of Three Hundred Fifty Thousand Dollars ($350,000) within three (3) days of execution of this
Agreement. Such option fee and the extension fee (described below), if paid, shall be fully credited against the License Fee under the future 

  
 4 

 
License Agreement. Payments drawn directly on a U.S. bank may be made by either check made payable to “Duke University” or wire transfer. Any payment drawn on a foreign bank or foreign
branch of a U.S. bank shall be made only by wire transfer. Wire transfers shall be made in accordance with the following or any other instructions as may be specified by DUKE. If payments are made by wire, the wiring instructions below must be
followed. The option granted herein shall not be effective until such delivery. 
  

			
	Bank:	  	Wells Fargo Bank, N.A.
		  	301 S. Tryon Street
		  	Charlotte, NC 28282, USA
	ABA #:	  	121000248 (Domestic wires only)
	Swift Code:	  	WFBIUS6S (Foreign wires only)
	Beneficiary:	  	Duke University Concentration Account
	Account #:	  	202374-0253053
	Attention:	  	Office of Licensing & Ventures, 919-681-7583* FILE NUMBER: 4719, 5000, 5191, 5204, 6381, 6382, 6478, 6479, 6480, 6622, 6623, 6624, 6625 and
7094

 4.2 OPTION PERIOD. This exclusive option shall be for a period of six (6) months from the EFFECTIVE DATE, subject
to extension by COMPANY as provided below (the “OPTION PERIOD”). Until expiration of the OPTION PERIOD, DUKE shall not enter into any discussions with any third party for any arrangement that if consummated would prevent from or interfere
with DUKE negotiating or entering into or carrying out the obligations contemplated in the terms and conditions described in Attachment A. 
 4.3 LIMITED
LICENSE. During the OPTION PERIOD, DUKE grants COMPANY the license to make, have made, or use the LICENSED PRODUCTS, LICENSED PROCESSES, REGULATORY DATA and TECHNICAL INFORMATION for the purposes described in Article 2 above. This limited
license does not include the right to grant any sublicenses, or to sell or otherwise provide LICENSED PRODUCTS or LICENSED PROCESSES to any third party. 

4.4 LICENSE NEGOTIATION. For a reasonable period of up to six (6) months after the EFFECTIVE DATE, (as may be extended by COMPANY for an additional
six (6) months by payment of a non-refundable $150,000 extension fee on or before the expiration of such six (6) months) the parties agree to negotiate exclusively in good faith to enter into the
License Agreement granting COMPANY exclusive rights to make, have made, import, use, market, offer for sale, and sell LICENSED PRODUCTS, and practice LICENSED PROCESSES under terms customary in the trade and including substantially the definitions
and terms in Attachment A. 
 4.5 NOTIFICATION OF LACK OF COMMERCIAL INTEREST: COMPANY shall promptly notify DUKE, during the OPTION PERIOD, in the
event that it determines that it has no commercial interest in the PATENT RIGHTS. 

  
 5 

 ARTICLE 5 - TERMINATION 

5.1 Except as otherwise provided herein, this Agreement shall terminate at the end of the OPTION PERIOD or upon execution of the License Agreement, whichever
occurs first. 
 5.2 If COMPANY ceases to operate its business, this Agreement shall immediately terminate upon DUKE’s delivery of a termination notice
to the address for notices provided herein. 
 5.3 Except as otherwise provided herein, if COMPANY fails to make any payment due to DUKE within ten
(10) days’ written notice by DUKE, this Agreement shall automatically terminate unless DUKE specifically extends such date in writing. Such termination shall not foreclose DUKE from collection of any amounts remaining unpaid or seeking
other legal relief. 
 5.4 Upon any material breach or default of this Agreement by COMPANY (other than as specifically provided herein, including
Section 5.3 above), the terms of which shall take precedence over the handling of any other material breach or default under this Section 5.4), DUKE has the right to terminate this Agreement effective on thirty (30) days’ written
notice to COMPANY, unless COMPANY cures the material breach or default before the period expires. 
 5.5 If COMPANY asserts the invalidity or
unenforceability of any claim included in the PATENT RIGHTS, including by way of litigation or administrative proceedings, either directly or through any other party, then DUKE shall have the right to immediately terminate this Agreement upon
written notice to COMPANY. 
 ARTICLE 6 - NO WARRANTIES; LIMITATION ON DUKE’S LIABILITY 

6.1 DUKE, including its trustees, fellows, officers, employees and agents, makes no representations or warranties that PATENT RIGHTS are or will be held
valid, or that the manufacture, importation, use, offer for sale, sale or other distribution of any LICENSED PRODUCTS or LICENSED PROCESSES will not infringe upon any patent or other rights. 

6.2 DUKE, INCLUDING ITS TRUSTEES, FELLOWS, OFFICERS, EMPLOYEES AND AGENTS, MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY
COMPANY OF LICENSED PRODUCTS OR LICENSED PROCESSES. COMPANY ASSUMES THE ENTIRE RISK AS TO PERFORMANCE OF LICENSED PRODUCTS AND LICENSED PROCESSES. It is expected that DUKE will make standard and customary
representations and warranties with respect to the subject matter of the License Agreement. 
 6.3 DUKE including its respective trustees, fellows,
officers, employees and agents, shall not be responsible or liable for any indirect, special, incidental, or consequential damages or lost profits or other economic loss or damage with respect to LICENSED PRODUCTS, LICENSED PROCESSES, or the PATENT
RIGHTS licensed to COMPANY under this Agreement, or other subject matter thereof, regardless of legal or equitable theory. The above limitations on liability apply even though DUKE, its trustees, fellows, officers, employees or agents may have been
advised of the possibility of such damage or such damage may have been foreseeable. 

  
 6 

 ARTICLE 7 - INDEMNIFICATION 

7.1 COMPANY shall defend, indemnify and hold harmless DUKE, including its trustees, officers, fellows, employees, students, contractors, subcontractors, and
agents against any and all damages, losses, and expenses of any nature (including attorney’s fees and other litigation expenses), resulting from including, but not limited to as a result of, death, personal injury, illness, property damage,
economic loss or products liability, including errors and omissions, arising from or in connection with any of the following: (1) any manufacture, use, sale, or other disposition by COMPANY of LICENSED PRODUCTS or LICENSED PROCESSES;
(2) the use by any person of LICENSED PRODUCTS or LICENSED PROCESSES made, used, sold, authorized, or otherwise distributed by COMPANY; (3) the use or practice of any invention related to the PATENT RIGHTS; provided that DUKE provides
COMPANY with prompt written notice of any such Claim, and cooperates with COMPANY as reasonably requested in any such defense or settlement; except in each case, to the extent a court of competent jurisdiction finds the sole cause of said Claim to
have been DUKE’s breach of this Agreement or the gross negligence or willful misconduct of DUKE, its employees or agents. This section does not confer any license rights on COMPANY, and shall survive termination or expiration of the Agreement.

 ARTICLE 8 - NOTICES 
 8.1 Any notice,
request, or report required or permitted to be given or made under this Agreement by either party is effective when mailed if sent by recognized overnight carrier, certified or registered mail, or electronic mail followed by confirmation by U.S.
mail, to the address set forth below or such other address as such party specifies by written notice given in conformity herewith. Any notice, request, or report not so given is not effective until actually received by the other party. 

 

			
	To DUKE:	  	To COMPANY:
		
	For delivery via the U.S. Postal Service	  	
		
	Office of Licensing & Ventures	  	Cryo-Cell International, Inc.
	Box 90083	  	700 Brooker Creek Blvd
	Durham, NC 27708	  	Oldsmar, FL 34677
	Attention: Agreement Manager/File No.	  	Attn: CEO
	4719, 5000, 5191, 5204, 6381, 6382, 6478, 6479, 6480, 6622, 6623, 6624, and 6625	  	
	  
 For delivery via nationally/internationally recognized
courier
  
 DUKE UNIVERSITY

Office of Licensing & Ventures

  
 7 

 2812 Erwin Road, Suite 406 

Durham, NC 27705 
 Attn: Agreement Manager/File No. 4719,
5000, 5191, 5204, 6381, 6382, 6478, 
 6479, 6480, 6622, 6623, 6624, and 6625 

For delivery via electronic mail 
 agreements-olv@duke.edu 
 ARTICLE 9 – MISCELLANEOUS PROVISIONS 

9.1 Each party agrees to accept all information, samples, documents, and other disclosures from the other party hereunder (hereinafter “Confidential
Information”) on a confidential basis only, and may not use Confidential Information of the other party for such party’s commercial benefit (except for technical and economic evaluation internal to COMPANY). Each party further agrees that
it will keep in confidence and not disclose Confidential Information of the other party to a third party or parties for a period of five (5) years from the end of the OPTION PERIOD. Any obligation set forth in this Section 9.1 does not
apply to any information which: (a) are or hereafter become a part of the public knowledge through no fault of the receiving party; (b) the receiving party can demonstrate were in its possession prior to the time of disclosure by the disclosing
party; (c) the receiving party can demonstrate were received by it from a third party who has a legal right to make such a disclosure; or (d) the receiving party can demonstrate by written evidence were developed by it independently of the
disclosure of Confidential Information by the disclosing party. 
 9.2 COMPANY shall not use, either directly or indirectly, the name of DUKE or any of its
trustees, officers, fellows or employees in any publicity or advertising unless a copy of the same is submitted to and approved in writing by DUKE prior to any such use. 

9.2 This Agreement shall be governed by and construed under the laws of the state of North Carolina without regard for principles of choice of law. Any claims,
demands, or actions asserted against DUKE, its trustees, fellows, officers, employees or agents shall only be brought in the North Carolina Court of Claims. COMPANY, its successors, and assigns consent to the jurisdiction of a court with applicable
subject matter jurisdiction sitting in the state of North Carolina with respect to any claims arising under this Agreement or the relationship between the parties. 

9.3 COMPANY may not assign this Agreement without the prior written consent of DUKE and shall not pledge any of the license rights granted in this Agreement as
security for any creditor; . Any attempted pledge of any of the rights under this Agreement or assignment of this Agreement without the prior consent of DUKE will be void from the beginning. No assignment by COMPANY will be effective until the
intended assignee agrees in writing to accept all of the terms and conditions of this Agreement, and such writing is provided to DUKE. 

  
 8 

 9.4 DUKE and COMPANY agree that this Agreement, together with Attachment A, sets forth their entire
understanding concerning the subject matter of this Agreement, and no modification of the Agreement will be effective unless both DUKE and COMPANY agree to it in writing. 

9.5 If a court of competent jurisdiction finds any term of this Agreement invalid, illegal or unenforceable, that term will be curtailed, limited or deleted,
but only to the extent necessary to remove the invalidity, illegality or unenforceability, and without in any way affecting or impairing the remaining terms. 

The authorized signatures for DUKE and COMPANY below signify their acceptance of the terms of this Agreement. 

 

									
	FOR COMPANY	 		 	FOR DUKE UNIVERSITY
					
	By:	 	 /s/ David Portnoy
	 		 	By:	 	 /s/ Robin L. Rasor

		 	(authorized representative)	 		 		 	Robin L. Rasor
		 		 		 	Executive Director
	Typed Name David Portnoy	 		 		 	
					
	Title	 	Chairman & Co-CEO	 		 		 	
					
	Date	 	June 9, 2020	 		 		 	Date June 9, 2020

  
 9 

 APPENDIX A. SUMMARY TERMSHEET 

DUKE FILE #’s 4719, 5000, 5191, 5204, 6381, 6382, 6478, 

6479, 6480, 6622, 6623, 6624, and 6625 

General 
  

			
	Technology:	  	Kurtzberg Cord Blood and Tissue Cell Products
		
		  	Patent Rights Group (A)
		
		  	 •  METHODS OF TREATING BRAIN INJURY USING CORD BLOOD OR A COMPONENT THEREOF, US
Application 16/477,110 (4719)

		
		  	 •  COMPOSITIONS AND METHODS OF THE TREATMENT OF DEMYLINATING CONDITIONS, US
Application 16/477,167, EP 18738872.3 (5000/5191)

		
		  	 •  METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS, PCT/US2018/022174, US
Application 16/493,754 (5204)

		
		  	Patent Rights Group (B)
		
		  	 •  METHODS OF TREATING CEREBRAL PALSY USING HIGH DOSE ALLOGENEIC UMBILICAL CORD
BLOOD, US Application 16/510,387 (6479)

		
		  	 •  METHODS OF TREATING CEREBRAL PALSY AND HYPOXIC-ISCHEMIC ENCEPHALOPATHY USING
HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS, PCT/US2019/025796 (6381)

		
		  	 •  METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS USING HUMAN UMBILICAL
CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS, PCT/US2019/025716 (6382)

		
		  	 •  COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINATING CONDITIONS US
Application 16/510,395

		
		  	 •  COMPOSITIONS COMPRISING MESESCHYMAL STROMAL CELLS FOR THE TREATMENT OF VIRAL
INFECTIONS US application 63/017,290

  
 10 

			
	DUKE will control the prosecution of any patent applications, provided DUKE will consult LICENSEE on the prosecution of PATENT RIGHTS under this agreement and keep LICENSEE fully informed with respect thereto. LICENSEE
will reimburse DUKE for its costs not yet reimbursed in seeking, prosecuting and maintaining PATENT RIGHTS and for its costs incurred during the term of the license agreement.
		
	“REGULATORY DATA”	  	includes copyrights and other intellectual property rights, to the extent owned by and/or (if any) licensed to DUKE under United States and international law, in any protocols, Standard Operating Procedures, case report forms, and
published data collected or created in connection with DUKE’s pre-clinical studies, regulatory submissions, and clinical trials (specifically IND numbers 14360, 16615, 15949, 17313, 17921, 16274, and
14753) and further includes any additional relevant TECHNICAL INFORMATION related to studies with Protocol Numbers 00017801, 00065043, 00052449, 00070514, 00079241, 00059284, 00077580, 00000412, and 00066647 including related reports, manuscripts
and correspondence and other records of regulatory interactions communicated by DUKE to LICENSEE under this License Agreement and at DUKE’s sole discretion, with initial reference in DUKE Office of Licensing and Ventures File Nos: 6480, 6622,
6623, 6624, and 6625. REGULATORY DATA and TECHNICAL INFORMATION shall not include the private medical records of individuals, and shall not include any data or information that allows such individuals to be directly identified.
		
	Technical Information:	  	means any non-patented scientific, technical, regulatory and other information to the extent owned by and/or (if any) licensed to DUKE and disclosed by DUKE to LICENSEE under this License
Agreement and at DUKE’s sole discretion. TECHNICAL INFORMATION does not include information that belongs in the public domain, as LICENSEE can show by documentary evidence.
		
	Licensed Rights: 	  	
		
		  	an exclusive worldwide license under Patent Rights B to make, have made, use, import, offer for sale, sell and otherwise commercially exploit LICENSED PRODUCTS and to practice LICENSED PROCESSES, and the exclusive right to use
REGULATORY DATA and TECHNICAL INFORMATION in connection with such licensed patent rights, in the FIELD OF USE and TERRITORY; and
		
		  	an exclusive license under Patent Rights A to make, have made, use, import, offer for sale, sell and otherwise commercially exploit LICENSED PRODUCTS and to practice LICENSED PROCESSES, and the exclusive right to use REGULATORY DATA
and TECHNICAL INFORMATION in connection with such licensed patent rights, in the FIELD OF USE and

  
 11 

			
		  	TERRITORY except for the EXCLUDED FIELDS OF USE in the EXCLUDED TERRITORY. For clarity, COMPANY shall have no LICENSED RIGHTS under Patent Rights A for the EXCLUDED FIELDS OF USE in the EXCLUDED TERRITORY; and
		
		  	in each case above with the right to sublicense; and
		
		  	subject to DUKE’s reserved rights to practice the LICENSED RIGHTS for all research, public service, internal (including clinical) and/or educational purposes; provided that DUKE shall keep COMPANY reasonably informed with
respect to any such practice and the results thereof and the COMPANY agrees to such activities, not to be unreasonably withheld.
		
		  	License is subject to any rights required to be granted under prior research or sponsorship agreements, or retained by the U.S. government, for example in accordance with Chapter 18 or Title 35 of USC
200-212 and the regulations thereunder (37 CFR Part 401), when applicable.
		
	Excluded Field of Use:	  	Autologous specific therapeutics for autism, Cerebral Palsy and stroke.
		
	Excluded Territory:	  	Japan, South Korea, and Taiwan
		
	Term of the License and Agreement:	  	Unless earlier terminated, will continue through the expiration of the royalty term upon which all licenses granted to COMPANY will become fully-paid up and irrevocable.
		
	Field of Use:	  	Human Therapeutics
		
	Net Sales:	  	will be defined in more detail in the License Agreement to include the amounts received, on sales, however characterized, by LICENSEE and/or SUBLICENSEES of LICENSED PRODUCTS and uses of LICENSED PROCESSES, less customary discounts
including the following deductions (but only to the extent such deductions are otherwise included in NET SALES and are not obtained in view of other consideration received by LICENSEE):
		
		  	 (a)   cash discounts, rebates and chargebacks actually granted to customers in
such invoices for SALE of LICENSED PRODUCTS, but only in amounts customary in the trade;

		
		  	 (b)   sales taxes, tariff duties and/or use taxes separately stated in such
bills or invoices with reference to particular SALES and actually paid by LICENSEE to a governmental unit;

  
 12 

			
		  	(c) actual freight expenses between LICENSEE and customers, to the extent such expenses are not charged to or reimbursed by customers; or
		
		  	(d) amounts actually refunded or credited on returns.
		
	Licensed Products:	  	means any product sold by LICENSEE or SUBLICENSEE that: (a) but for this Agreement comprises an infringement of (including contributory or inducement), or is covered by, a VALID CLAIM contained in the PATENT RIGHTS in the
country in which any such product or product part is made, used, imported, offered for SALE or sold; or (b) is manufactured or is administered to a patients by using a LICENSED PROCESS or is employed to practice a LICENSED PROCESS; or (c) uses
any of the REGULATORY DATA or TECHNICAL INFORMATION.
		
	Licensed Process:	  	means any process or method or service employed by LICENSEE or SUBLICENSEE that: (a) but for this Agreement, comprises an infringement of (including contributory or inducement or is covered by a VALID CLAIM contained in the
PATENT RIGHTS in the country in which such process or method or service is performed; or (b) employs a LICENSED PRODUCT; (c) uses any of the REGULATORY DATA or TECHNICAL INFORMATION.
		
	Valid Claim	  	means (a) a claim in an issued patent which has not (i) expired, (ii) been finally adjudicated or admitted by DUKE as invalid or unenforceable, or (iii) been abandoned, or (b) a claim in a pending application which is
still under prosecution. It is understood and agreed that a claim in a pending application that is subject to a restriction requirement during prosecution and is not yet being prosecuted as part of a divisional patent application will still be
considered a Valid Claim until it is finally rejected or abandoned.
		
	First Commercial Sale:	  	means the first SALE through a bona fide arm’s length transaction of any LICENSED PRODUCT or first commercial use of any LICENSED PROCESS by LICENSEE or a SUBLICENSEE, excluding the SALE of a LICENSED PRODUCT or use of a
LICENSED PROCESS for use in trials, as a sample, or that is of temporary availability.
		
	Market Cap:	  	means, with respect to a particular trading day, the closing price per share of common stock on such trading day multiplied by the number of outstanding shares.
		
	Royalty Term	  	Means 15 years post first commercial sale or expiration of the last VALID CLAIM, whichever comes later.

  
 13 

 Consideration 

License Fee: $12,000,000 (12 million dollars) of which $5 million will be due upon signing, $5 million will be due on the first anniversary of
the LICENSE EFFECTIVE DATE and $2 million will be on the second anniversary date of the License EFFECTIVE DATE. License Fee shall be non-refundable, non-creditable.
If LICENSEE terminates the License Agreement prior to three (3) years from the EFFECTIVE DATE, LICENSEE will pay DUKE the balance of License Fee owed above within thirty (30) days of said termination and receipt of invoice therefor. 

 

			
	Board Observation Rights.	  	DUKE shall have observation rights at any of LICENSEE’s Board of Directors meetings. At such meetings, DUKE, at its option, shall be permitted to have a non-voting designee (the
“Observer”) attend in-person or via telephone for sessions covering matters relating to LICENSEE’s business, provided that: (i) the Observer will be excused from any Board activities
involving attorney-client privilege or otherwise determined by the Board consistent with good corporate governance (including any executive or closed sessions) and (ii) such rights shall terminate on the earliest of a Change of Control of
LICENSEE, or such time as DUKE’s equity interest in LICENSEE is less than two percent (2%) (on a fully-diluted basis). Any such Observer will enter into an agreement with LICENSEE on customary terms for observers to protect confidential
information of LICENSEE.
		
	Royalties:	  	For NET SALES of LICENSED PROCESS:
		  	7% of annual NET SALES up to $75M
		  	10% on annual NET SALES at or above $75M and up to $200M
		  	12.5% on annual NET SALES at or above $200M
		  	*Royalties shall be reduced to 75% of the above rates after expiration of all PATENT RIGHTS but prior to 15 years post FIRST COMMERCIAL SALE.
		
		  	For NET SALES of LICENSED PRODUCT:
		  	7.5%
		  	*Royalty reduced to 2.5% after expiration of all PATENT RIGHTS but prior to 15 years post FIRST COMMERCIAL SALE.

  
 14 

 If, in the performance of a LICENSED PROCESS, a LICENSED PRODUCT is administered, the NET
SALES of such LICENSED PROCESS shall be in addition to the use or administration of such LICENSED PRODUCT. For purposes of calculating 

royalties for the use or administration of a LICENSED PRODUCT by LICENSEE or its Affiliates in the performance of said LICENSED PROCESS shall
constitute a third party sale of said LICENSED PRODUCT. NET SALES in such an instance shall be the average selling price of like quantities of LICENSED PRODUCTS sold in the United States during the reporting period in which such LICENSED PRODUCT was
used or administered in the performance of such LICENSED PROCESS. The License Agreement will include customary combination sales terms for standard allocation of Net Sales. 

If LICENSEE is obligated or reasonably deems it necessary to pay consideration to any Third Party that holds a patent(s) that would, in the
reasonable judgment of LICENSEE be infringed by the manufacture, importation, use, offer for sale or sale of a LICENSED PRODUCT or LICENSED PROCESS, then LICENSEE shall be entitled to deduct fifty percent (50%) of such consideration paid to such
Third Party from the royalties payable to DUKE. However, in no event shall the royalty payable to DUKE for any ROYALTY PERIOD be reduced to less than fifty percent (50%) of the agreed upon royalty rates of NET SALES. LICENSEE shall provide DUKE with
a copy of any agreement with a Third Party that triggers the royalty reduction, provided that LICENSEE may redact from such copy any provisions LICENSEE considers confidential or proprietary that are not necessary to verify the accuracy of such
deductions When LICENSEE finalizes the formulation of any LICENSED PRODUCT during the product development cycle, LICENSEE shall promptly inform DUKE of any Third Party patent rights required for the LICENSED PRODUCT and the applicable royalty rates
therefore. In addition, should LICENSEE subsequently determine that any additional Third Party patent rights are required, LICENSEE shall promptly inform DUKE. 
  

			
	Sublicensing Income	  	35% of any consideration not based on NET SALES (e.g., license issue fees, milestone payments, maintenance or annual minimum fees, other royalties) received from Sublicensees in consideration for the LICENSED RIGHTS, other than
R&D funds and other customary carveouts to be specified in the License Agreement.
		
	Minimum Annual Royalties:	  	Such minimum annual royalties to be paid provided the FDA allows the IND transfer and does not revoke the expanded access for reasons unrelated to LICENSEE

 (1) In year 2: $500,000 

(2) In Year 3: $1.0M 
 (3) In
Year 4: $2.5 M 
 (4) In Year 5 and Beyond: $5.0 M 

Minimum Annual Royalties shall be credited against Running Royalties due on NET SALES made during the calendar year for which the Minimum Annual Royalties
apply. Minimum Annual Royalties paid in excess of running royalties shall be creditable to amounts due for future years. 

  
 15 

			
	Milestone Payments:	  	Cash
		
		  	 •  $2.0M upon initiation of a Phase III clinical trial for an indication other
than Autism Spectrum Disorder for a Licensed Product comprising cord tissue derived MSC

		
		  	CryoCell Stock
		
		  	 •  5.0% of common stock upon execution of License Agreement

		
		  	 •  2.5% of common stock upon cumulative NET SALES of LICENSED PRODUCT and
LICENSED PROCESS of $10M

		
		  	 •  2.5% of common stock upon cumulative NET SALES LICENSED PRODUCT and LICENSED
PROCESS of $75M

		
		  	 •  2.5% of common stock at each of the following market cap of LICENSEE
triggers:

		
		  	 (1) at $300M as long as this milestone is reached within 18 months of the execution of the agreement

		
		  	 (2) at 500M as long as this milestone is reached within 24 months of the execution of the agreement

 In the event a Sublicensee pays LICENSEE a fee for achieving one of the milestone events listed above or under earned
royalties, or a substantially similar milestone, LICENSEE shall pay 35% of the higher of: (i) the milestone payment or (ii) the Non-Sales Based Sublicense Income fee due on such Milestone Payment.

 Milestone payments are non-refundable and non-creditable. 

Diligence 
 LICENSEE shall use
commercially reasonable efforts to bring LICENSED PRODUCTS to market or one or more LICENSED PROCESSES to commercial use through use of commercially reasonable efforts to (i) implement a thorough, vigorous and diligent program for exploiting
the PATENT RIGHTS and (ii) to continue active, diligent marketing efforts throughout the life of this Agreement. 
  

			
	Milestones:	  	Performance milestones are established to ensure that the technology is assiduously developed and to ensure broad public utilization of the technology.

  
 16 

			
		  	In fulfillment of such milestones, LICENSEE agrees to reach the following commercialization and research and development milestones by the following dates:
		
		  	 1) Auto- Milestones to be agreed upon between DUKE and LICENSEE (development/sales/clinic driven)

		
		  	 2) Allo- Milestones to be agreed upon between DUKE and LICENSEE (development/sales/clinic driven)

		
		  	 3) MSC- Milestones to be agreed upon between DUKE and LICENSEE
(development/manufacturing/sales driven)

 Other Terms 
  

			
	Insurance:	  	Prior to any distribution or commercial use of LICENSED PRODUCTS or LICENSED PROCESSES resulting from PATENT RIGHTS by LICENSEE, LICENSEE shall purchase and maintain in effect policies of product liability, completed operations, and
errors and omissions insurance.
		
	Indemnification:	  	LICENSEE shall defend, indemnify and hold harmless and shall require SUBLICENSEES to defend, indemnify and hold harmless DUKE for and against any and all claims, demands, damages, losses, and expenses of any nature (including
attorneys’ fees and other litigation expenses) (hereinafter “Claim”), resulting from, but not limited to, death, personal injury, illness, property damage, economic loss or products liability, including errors and omissions, arising
from or in connection with, any of the following: (1) Any manufacture, use, SALE or other disposition by LICENSEE, SUBLICENSEES or transferees of LICENSED PRODUCTS or LICENSED PROCESSES; (2) The use by any person of LICENSED PRODUCTS made,
used, sold or otherwise distributed by LICENSEE or SUBLICENSEES; (3) The use or practice by LICENSEE or SUBLICENSEES of any invention or computer software related to the PATENT RIGHTS; and (4) any Claim of infringement and/or invalidity of
any claim(s) of the PATENT RIGHTS. The process for such indemnification to be set forth in the License Agreement.
		
	Assignment	  	LICENSEE agrees that these license rights are not assignable without written consent from DUKE except in connection with a change of control (to be defined in the License Agreement).
		
	Spin-out	  	If LICENSEE takes part in the formation of a Spinout for purposes of exploiting the license granted to LICENSEE, LICENSEE shall cause the Spinout to transfer to DUKE by the later of (a) sixty (60) days after a sublicense to the
PATENT RIGHTS or assignment of this LICENSE AGREEMENT becomes effective between LICENSEE and the Spinout,

  
 17 

			
		  	or (b) the Spinout is first capitalized with at least $X million by a Third Party investor(s), a total of X percent (%) share of the equity interest in the Spinout. The equity received by DUKE in the Spinout shall be of the
same type (e.g., class of stock) received by LICENSEE under the relevant sublicense transaction. If the Spinout is a corporation, then the parties agree that LICENSEE, or the Spinout, shall make such transfer of equity pursuant to, and subject to
the terms of, an agreement substantially in the form of a Stock Transfer Agreement as attached in Appendix X. If the Spinout is of another legal form, then the parties shall negotiate in good faith as to the terms of the transfer of
equity.
		
	Warranty:	  	EXCEPT FOR THOSE REPRESENTATIONS AND WARRANTIES THAT ARE CUSTOMARY FOR SIMILAR TRANSACTIONS, DUKE, INCLUDING ITS TRUSTEES, OFFICERS, EMPLOYEES STUDENTS AND AGENTS, MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION
BY LICENSEE OR SUBLICENSEES OF LICENSED PRODUCTS OR LICENSED PROCESSES.
		
		  	LICENSEE, AND SUBLICENSEES ASSUME THE ENTIRE RISK AS TO PERFORMANCE OF LICENSED PRODUCTS AND LICENSED PROCESSES. In no event shall DUKE, including its trustees, fellows, officers, employees and agents, be responsible or liable for
any indirect, special, incidental, or consequential damages or lost profits or other economic loss or damage with respect to LICENSED PRODUCTS or LICENSED PROCESSES, to LICENSEE, Sublicensees or any other individual or entity regardless of legal or
equitable theory.
		
	Other Terms:	  	Other typical terms to be negotiated.

  
 18ctrn_Ex10_2

		
			Exhibit 10.2
		

		
			PERFORMANCE-BASED
		

		
			RESTRICTED STOCK UNIT AWARD AGREEMENT
		

		
			Non-transferable Grant to
		

		
			(“Grantee”)
		

		
			by Citi Trends, Inc. (the “Company”) of
		

		
			______  restricted stock units (the “Units”) representing the right to earn, on a one-for-one basis, shares of the Company’s common stock (“Shares”) , as provided herein, pursuant to and subject to the provisions of the Citi Trends 2012 Incentive Plan (the “Plan”), and to the terms and conditions set forth on the following page of this Agreement (the “Agreement”).
		

		
			The target number of Shares subject to this award is _____ (the “Target Award”).  Depending on the Company’s level of attainment of achievement Adjusted EBIT (as defined in Section 14 of the terms and conditions of this Agreement) for the fiscal year ended February 4, 2023 (“fiscal 2022”) as set forth on Exhibit A, and subject to Grantee’s remaining in Continuous Service with the Company through such date, Grantee may earn and vest in between 0% and 200% of the Target Award, subject to the terms and conditions of this Agreement.
		

		
			By accepting the Units, Grantee shall be deemed to have agreed to the terms and conditions of this Agreement and the Plan.  Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan.
		

		
			IN WITNESS WHEREOF, the Company, acting by and through its duly authorized officers, has caused this Agreement to be duly executed.
		

			
					
						 

					
					
						Grant Date of Award: March 10, 2020

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						CITI TRENDS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						David Makuen, Chief Executive Officer

				

		
			 
		

		
			 
		

		

		 

	
					
						

					
						TERMS AND CONDITIONS

					
						1.  Grant of Units.  The Company hereby grants to Grantee, subject to the restrictions and the terms and conditions set forth in the Plan and in this Agreement, the number of Units indicated on page 1 hereof which represent the right to receive shares of the Company’s Stock.  

					
						2.  Vesting of Units.  The Units have been credited to a bookkeeping account on behalf of Grantee.  The Units will vest and become non-forfeitable on the earliest to occur of the following (each, a “Vesting Date”):

					
						(a)    as to the number of Units earned based on the Company’s level of attainment of achievement Adjusted EBIT fiscal 2022 as set forth on Exhibit A, on the date of the Company’s earnings release for fiscal 2022, subject to either (i) Grantee’s Continuous Service with the Company through such date, or (ii) termination of Grantee’s Continuous Service prior to such date by reason of Grantee’s death or Disability;

					
						(b)    as to the number of Units equal to the Target Award, on the occurrence of a Change in Control, unless the Units are assumed by the surviving entity or otherwise equitably converted or substituted in connection with the Change in Control, and subject to Grantee’s Continuous Service on the date of the Change in Control; or  

					
						(c)    as to the number of Units equal to the Target Award, if the Units are assumed by the surviving entity or otherwise equitably converted or substituted in connection with a Change in Control, on the termination of Grantee’s employment by the Company without Cause (or Grantee’s resignation for Good Reason as provided in any employment, severance or similar agreement between Grantee and the Company or an Affiliate) within twelve (12) months after the effective date of the Change in Control.

					
						Any Units that fail to vest in accordance with the terms of this Agreement will be forfeited and reconveyed to the Company without further consideration or any act or action by Grantee.

					
						3. Termination of Continuous Service.  If Grantee’s employment is terminated for any reason other than death or Disability prior to the Vesting Date, then all of the Units will be forfeited and reconveyed to the Company on the date of termination without further consideration or any act or action by Grantee.

					
						4.  Conversion to Stock.  Unless the Units are forfeited prior to the Vesting Date as provided in section 3 above, the Units will be converted on the Vesting Date to actual shares of Stock, and such Shares will be registered on the books of the Company in the name of Grantee (or in street name to Grantee’s brokerage account) as of the Vesting Date in uncertificated (book-entry) form unless Grantee requests a stock certificate or certificates for the Shares.  

					
					
						    

					
					
						5. Dividend Rights.  Grantee shall accrue cash and non-cash dividends, if any, paid with respect to the Stock, but the payment of such dividends shall be deferred and held (without interest) by the Company for the account of Grantee until the expiration of the restrictions set forth in this award agreement.  Such dividends shall be subject to the same vesting restrictions as the Stock to which they relate.  Accrued dividends deferred and held pursuant to the foregoing provision shall be paid by the Company to the Grantee promptly upon the expiration of the restrictions set forth in this award agreement (and in any event within 30 days of the date of such expiration).

					
						6.  Restrictions on Transfer.  No right or interest of Grantee in the Units may be pledged, hypothecated or otherwise encumbered to or in favor of any party other than the Company or an Affiliate, or be subjected to any lien, obligation or liability of Grantee to any other party other than the Company or an Affiliate.  Units are not assignable or transferable by Grantee other than by will or the laws of descent and distribution.  

					
						7.  Limitation of Rights.  The Units do not confer to Grantee or Grantee’s beneficiary any rights of a stockholder of the Company unless and until shares of Stock are in fact issued to such person in connection with the Units.  Nothing in this Agreement shall interfere with or limit in any way the right of the Company to terminate Grantee’s employment at any time, nor confer upon Grantee any right to continue in the employ of the Company.

					
						8.  Payment of Taxes.  Grantee will, no later than the date as of which the Units first become includable in Grantee’s gross income for federal income tax purposes, pay to the Company, or make other arrangements satisfactory to the Committee regarding payment of, any federal, state and local taxes of any kind required by law to be withheld with respect to such amount.  To the extent not prohibited by applicable laws or regulations, Grantee may elect that any such withholding requirement be satisfied, in whole or in part, by having the Company withhold from the Units upon settlement a number of shares of Stock having a Fair Market Value on the date of withholding, equal to the minimum amount (and not any greater amount) required to be withheld for tax purposes, all in accordance with such procedures as the Committee establishes.  The obligations of the Company under this Agreement will be conditional on such payment or arrangements, and the Company will, to the extent permitted by law, have the right to deduct any such taxes from the award or any payment of any kind otherwise due to Grantee. 

					
						Unless otherwise determined by the Committee, the withholding requirement shall be satisfied by withholding Shares having a Fair Market Value on the date of withholding equal to the amount required to be withheld in accordance with applicable tax requirements.

					
					
						    

					
					
						9.  Amendment.  The Committee may amend, modify or terminate this Certificate without approval of Grantee; provided, however, that such amendment, modification or termination shall not, without Grantee’s consent, reduce or diminish the value of this award determined as if it had been fully vested (i.e., as if all restrictions on the Units hereunder had expired) on the date of such amendment or termination.

					
						10.    Plan Controls.  The terms contained in the Plan are incorporated into and made a part of this Agreement and this Agreement shall be governed by and construed in accordance with the Plan.  In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall be controlling and determinative.

					
						11.  Successors.  This Agreement shall be binding upon any successor of the Company, in accordance with the terms of this Agreement and the Plan.

					
						12.  Severability.  If any one or more of the provisions contained in this Agreement is invalid, illegal or unenforceable, the other provisions of this Agreement will be construed and enforced as if the invalid, illegal or unenforceable provision had never been included.

					
						13. Notice. Notices and communications under this Agreement must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to Citi Trends, Inc., 104 Coleman Blvd. Savannah, GA 31408, Attn: Secretary, or any other address designated by the Company in a written notice to Grantee. Notices to Grantee will be directed to the address of Grantee then currently on file with the Company, or at any other address given by Grantee in a written notice to the Company.

					
						14. Definition of Adjusted EBIT.  For purposes of this Agreement, “Adjusted EBIT” means EBIT as adjusted for certain other unusual or non-recurring items (including, but not limited to, unplanned and significant costs related to litigation, claim judgements, settlements or proxy contests). Such adjustments for unusual or non-recurring items must have also been approved as adjustments by the Committee for the calculation of bonuses under management’s annual cash incentive program for the fiscal year under which Adjusted EBIT is being calculated for this Agreement. 

				

		
			 
		

		
			 
		

		
			

		 

		

		
			EXHIBIT A
		

		
			Performance Matrix for Determining Number of Earned Units
		

			
					
						 

					
					
						 

				
	
					
						Adjusted EBIT for Fiscal 2022 

					
					
						Percentage of Target Award Earned (1)

				
	
					
						Less than $29,757,000

					
					
						0%

				
	
					
						$29,757,000

					
					
						50%

				
	
					
						32,700,000

					
					
						100%

				
	
					
						$44,472,000

					
					
						200%

				

		
			 
		

			
	
			
				 (1)
			Payouts between performance levels will be determined based on straight line interpolation.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]